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INTRODUCTION
Increased airway smooth muscle (ASM) mass and
airway remodelling is a common feature in chronic air-
way diseases such as asthma (1). Airway remodelling is
accompanied with angiogenesis and microvascular
changes wherein the ongoing inflammation seems to be
the main contributing factor (2–5). Evidence suggests
that the number and size of bronchial vessels is moder-
ately increased in patients with asthma as compared
with normal individuals (6–9). Moreover, Salvato and
colleagues (10) found that patients with severe asthma
had significantly more vessels than those with a mild or
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moderate disease. Previously, we reported that fibrob-
last growth factors (FGFs) and vascular endothelial
growth factor (VEGF) play a pivotal role in the patho-
genesis of chronic obstructive pulmonary disease
(COPD) (2,3). Similarly, enhanced bronchial local-
ization of various angiogenic growth factors has been
observed in patients with asthma and COPD
(2,3,11,12). However, the molecular mechanisms under-
lying bronchial angiogenesis and vascular remodelling
remain unclear.
VEGF is a potent endothelial cell mitogen that regu-
lates vasculogenesis and postnatal vascular remodeling
(13). Expression of VEGF is upregulated under a variety
of pathophysiological conditions, including hypoxia in
the lung (14) and during angiogenesis in other biologi-
cal systems (15,16). The most important role of VEGF in
inflammation may be in mediating the angiogenic
response (17). Because angiogenesis and increased vas-
cular permeability are characteristic features of wound
healing, VEGF may play an important role in airway
remodeling in asthma, where wound healing after
injury is a common phenomenon (12). VEGF is
expressed by human ASM cells in culture and in lungs
under pathophysiological conditions (2,9,18,19), and we
have shown that COPD is associated with an increased
expression of VEGF in both ASM and vascular smooth
muscle (VSM) cells in bronchiolar as well as alveolar
regions; this increased expression is inversely correlated
with the lung function data (2).
Angiotensin (ANG)II and endothelin (ET)-1 are
potent vasoconstricting circulatory hormones impli-
cated in asthma (20–24). ANG II has been reported to
induce VEGF mRNA expression in rat heart endothelial
cells (25) and mitogenesis in human ASM cells (26).
Evidence suggests that ET-1 acts as a co-mitogen with
EGF and that its action is mediated through activation
of ETA receptors in lungs (27). However, the underlying
molecular mechanisms of mitogenic and subsequent
signalling elicited by ET-1 in human ASM cells are not
yet characterized. We therefore investigated the
responses to ANG II and ET-1 in human ASM cells in
vitro and examined the expression and release of VEGF
that may contribute to pulmonary vascular remodeling
in chronic airway diseases. Furthermore, we assessed
the conditioned medium obtained from human ASM
cells treated with ANG II and ET-1 for in vitro angio-
genic potential by examining endothelial cell prolifera-
tion and growth.
MATERIALS AND METHODS
Human ASM Cell Isolation and Culture
Human ASM cells were isolated and cultured as
described previously (28). Briefly, bronchial smooth
muscle was dissected from fresh macroscopically nor-
mal lobar or main bronchi. After removal of the epithe-
lium, parts of smooth muscle was dissected, free of
adherent tissue under aseptic conditions. Smooth mus-
cle pieces were incubated in Hank’s balanced salt solu-
tion (HBSS; Invitrogen, Breda, The Netherlands)
containing bovine serum albumin (BSA, 10 mg/mL),
collagenase (type XI, 1 mg/mL) and elastase
(3.3 U/mL; Sigma-Aldrich BV, Zwijndrecht, The
Netherlands) at 37°C in a humidified incubator con-
taining 5% CO2/95% air for 30 min. After enzymatic
digestion, the cell suspension was centrifuged and the
pellet was washed in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Breda, The Netherlands)
containing 10% (v/v) heat-inactivated fetal bovine
serum (FBS; Cambrex, Verviers, Belgium) supple-
mented with sodium pyruvate (1 mM), nonessential
amino acid mixture (1:100), gentamicin (45 µg/mL),
penicillin (100 U/mL), streptomycin (100 µg/mL), and
amphotericin B (1.5 µg/mL) (Invitrogen, Breda, The
Netherlands). Cells were subsequently seeded at 2 ×
105 cells per 35-mm dish and maintained in culture by
replacing the medium every 48 h. After 10–14 d in cul-
ture, ASM cells grew to confluence and were then
detached by trypsinization (0.5% trypsin; 0.02% EDTA;
Invitrogen, Breda, The Netherlands) and subcultured
into 25-cm2 and 75-cm2 tissue-culture flasks. 
Immunocytochemical Characterization 
of Cultured Human ASM Cells
Immunocytochemical staining of confluent serum-
deprived primary cultures of human ASM cells, using
monoclonal antibodies to smooth muscle α-actin and
smooth muscle-myosin heavy chain (SM1 and SM2;
Sigma-Aldrich BV, Zwijndrecht, The Netherlands)
demonstrated that the cultures were essentially free
(<5%) of other contaminating cell types (26,28). In order
to perform immunocytochemistry, monoclonal anti-
bodies against α-smooth muscle actin were used as
markers. In brief, cells were allowed to attach to multi-
well slides for 24 h in FBS-containing medium and
were subsequently growth-arrested by incubating for
60–72 h in FBS-free DMEM supplemented with apo-
transferrin (5 µg/mL), ascorbate (100 µM), and insulin
(1 µM) prior to fixation and staining. Following two
washes in ice-cold phosphate-buffered saline (PBS; 140
mM NaCl, 2.6 mM KCl, 1.4 mM KH2PO4, 8.1 mM
Na2HPO4 · 2 H2O, pH 7.4), the cells were fixed in ice-
cold methanol and permeabilized in PBS containing
0.1% Tween-20. Nonspecific bindings were blocked by
incubating the cells in 1% BSA in PBS, and the cells
were then washed and subsequently incubated with
anti-α-smooth muscle actin antibodies. The cells were
then washed twice in PBS and further incubated with
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affinity purified fluorescein isothiocyanate (FITC)-con-
jugated antimouse antibody. Unbound antibody was
washed away using distilled water and the sections
were dehydrated and mounted in glycerol. Specimens
were visualized under a fluorescence microscope (Carl
Zeiss BV, Weesp, The Netherlands) and photographed.
Human ASM cells stained positive for anti-µ-smooth
muscle actin (Fig. 1, upper right panel). Under the light
microscope, the human ASM cells appeared elongated
and spindle-shaped with central oval nuclei containing
prominent nucleoli. Confluent human ASM cells in cul-
ture showed a specific pattern, aligned in parallel so
that the broad nuclear region of one cell lies adjacent to
the thin cytoplasmic area of another, giving rise to a
typical “hill and valley” appearance (Fig. 1, upper left
panel). 
Porcine Pulmonary Artery Endothelial Cell
Isolation and Culture
The lungs were obtained from Yorkshire × Landrace
female pigs after sacrifice and the major pulmonary
artery was identified and dissected free of all connec-
tive tissue and cleaned with HBSS. After incubation
with collagen I for 30 min, endothelial cells were iso-
lated by scraping gently the inner surface of the artery
with a surgical blade and cultured up to fourth passage
in M-199 medium containing 10% fetal calf serum (FCS;
Cambrex, Verviers, Belgium) at 37°C in a 5% CO2-
humidified atmosphere. Cells were maintained in cul-
ture by replacing the medium every 48 h and when
confluent was further passaged using trypsin/EDTA
solution into 75-cm2 tissue culture flasks. Porcine pul-
monary artery endothelial cells had the characteristic
cobblestone appearance when cultured in monolayer.
Cells were characterized immunocytochemically, using
monoclonal antibodies against CD31 and visualized
under the light microscope. Porcine pulmonary artery
endothelial cells in culture revealed cobblestone
appearance (Fig. 1, lower left panel). Immunocyto-
chemical staining of confluent serum-deprived primary
cell cultures of using monoclonal antibodies against
CD31 (Fig. 1, lower right panel) demonstrated that the
cultures were essentially free (<5%) of other contami-
nating cell types.
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Fig. 1. Representative examples of human airway smooth muscle (ASM) and pulmonary artery endothelial cells in cul-
ture. Photomicrograph depicts the monolayer (upper left panel) of human ASM cells with the characteristic hill and valley
appearance. Smooth muscle α-actin (fluorescence) antibody (upper right panel) characterizes the staining in longitudinal
actin filaments and assures the purity of the human ASM cells. Photomicrograph depicts the monolayer (lower left panel)
of porcine pulmonary artery endothelial cells (PAEC) with the characteristic cobble stone appearance. CD31 (brown) anti-
body staining (lower right panel) characterizes the purity of the endothelial cells.
Stimulation of Human ASM Cells In Vitro 
With ANG II or ET-1
Human ASM cells were added in 500 µL medium to
a 24-well multiplate (Corning BV, Schiphol, The
Netherlands), at a final concentration of 3 × 104
cells/well. After 72 h, cells were serum deprived for
60 h and subsequently incubated with optimal concen-
tration of ANG II (100 nM) or ET-1 (10 nM), based on
previous reports (26,29) and by pilot experiments, for 30
min, 1, 2, 4, 8, 16, and 24 h. Control cells were cultured
in serum-free medium (24 h).
Isolation of Total Cellular RNA 
and Northern Blot Analysis
Total RNA was extracted from the cells incubated
with ANG II (100 nM) or ET-1 (10 nM) for 30 min, 1, 2,
4, 8, 16, and 24 h by the guanidinium thiocyanate-phe-
nol-chloroform method. For Northern hybridization,
10 µg of total RNA was electrophoresed on 1% agarose
gel containing 2.2 M formaldehyde. RNA was trans-
ferred to hybond-N membranes, which were eventu-
ally ultraviolet cross-linked and hybridized at 42°C.
cDNA insert (950 bp DNA fragment encoding human
VEGF) was labeled using (32P)dCTP with a multiprime
labeling system. Filters were washed under stringent
conditions and subsequently exposed to Kodak
X-OMAT AR films at –80°C. A glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) cDNA probe was used
to rehybridize membranes for reference purposes. After
autoradiography and densitometric measurement of
signals, the optical density (OD) of the VEGF signal
was divided by OD of the corresponding GAPDH sig-
nal and relative mRNA levels were calculated. Values
were expressed as fold induction (mean ± SEM) from
four different autoradiograms. Statistical significance
was accepted at p ≤ 0.05.
Measurement of VEGF Protein by Enzyme-Linked
Immunosorbent Assay
Conditioned media were collected from human ASM
cells treated with ANG II or ET-1 and VEGF levels were
assessed using a commercial enzyme-linked immuno-
sorbent assay (ELISA) kit according to the manufac-
turer’s instruction (R&D Systems, Abington, UK). As a
control, conditioned medium from human ASM cells
incubated with only serum-free medium was used.  A
standard curve using recombinant VEGF protein was
first established and subsequently, 100 µL of condi-
tioned medium was used to assay VEGF. Subsequently,
the samples were pre-incubated with VEGF capture
antibody followed by biotinylated VEGF-detecting anti-
body. After addition of the streptavidine–peroxidase
conjugate, tetramethylbenzidine (TMB) was added and
the absorbance of the resulting colored product was
measured using an automated spectrophotometer
(Biorad Laboratories BV, Veenendaal, The Netherlands).
The concentration of VEGF was expressed in ng/mL.




IN HUMAN ASM CELLS TREATED WITH ET-1
Effects of ET-1 on human ASM DNA biosynthesis
were evaluated by incorporation of [methyl-3H]-thymi-
dine. Confluent cells were washed in PBS, loosened by
trypsinization, and transferred into 96-well plates at a
seeding density of 1 × 104 cells/well. After 24 h in cul-
ture, the subconfluent cell monolayers were growth
arrested by 48 h serum deprivation and incubated with
different concentrations of ET-1 (1, 10, and 100 nM) for
48 h. Additionally, cells were incubated with ET-1 (10
nM) for time periods varying from 24 to 96 h. Five
hours prior to the end of the treatment periods, 10 µL (1
µCi/10 µL in HBSS) of [3H]-thymidine was added to
the wells, at a final concentration of 1 MCi/110 µL per
well. The plates were frozen overnight at –20°C, after
which the cells were harvested on glass fibre filters
using a Filtermate 196 cell harvester (Packard,
Meridan, USA) and the activity was counted using a
Microplate Scintillation β-counter (Topcount, Packard,
Meridan, USA). Measured radioactivity was expressed
as counts per min (CPM). Data represented is the mean
CPM of experiments performed with three different
cell isolations.
ENDOTHELIAL CELL PROLIFERATION ASSAY
Porcine pulmonary artery endothelial cells were
added in 100 mL medium to a 96-well multiplate
(Corning BV, Schiphol, the Netherlands) at a final con-
centration of 1 × 104 cells/mL. After 48 h, the cells were
serum deprived for 24 h and subsequently incubated
with the conditioned medium from human ASM cells
treated for 8 h with ANG II (100 nM) or ET-1 (10 nM)
and positive controls with VEGF (5 ng/mL) or placental
growth factor (PlGF) (5 ng/mL) in 100 µL serum-free
M199 medium for 24 h. Control incubations consisted of
cells that were incubated with serum-free M199
medium alone. DNA biosynthesis was measured
employing [3H]-thymidine incorporation assay as
described above.
ENDOTHELIAL CELL COUNT
In a parallel series of experiments, serum-deprived
porcine pulmonary artery endothelial cells were stimu-
lated with the same factors as above for 48 h and
processed for cell counting in the Casy®1 system
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(Schärfe system GmbH, Reutelingen, Germany). After
stimulation, cells were harvested with mild trypsinisa-
tion. Cells in suspension were added to 10 mL of Casy1
isotonic solution (6.38 g/L NaCl, 0.2 g/L Na-tetrabo-
rate, 1.0 g/L Boric acid, and 0.2 g/L EDTA), counted
and further analyzed using Casy1 system software.
VEGF Receptor Blockade and Endothelial 
Cell Growth
Human umbilical vein endothelial cells (HUVECs)
were isolated from normal human umbilical cords as
described earlier (30). Briefly, cells were cultured in
fibronectin-coated tissue-culture flasks in culture
medium (human endothelial-SFM, Invitrogen), with
20% newborn calf serum, 10% human serum
(Cambrex, Verviers, Belgium), 20 ng/mL basic FGF,
and 100 ng/mL epidermal growth factor (Peprotech,
London, UK). Passages 5 to 7 were used for the exper-
iments. Cells were plated in fibronectin-coated 96-
well plates and allowed to grow for 24 h and then
serum-deprived and cultured in DMEM for 24 h.
Serum-deprived cells were incubated for 48 h with
control medium (DMEM alone) or the conditioned
medium from ET-1 (10 nM)-treated (8 h) human ASM
cells in 1:1 dilution. Control HUVECs were exposed to
medium from untreated ASM cells. Activity of VEGF
present in the conditioned medium on the growth of
HUVECs was assessed by pretreating the cells with 10
µM VEGF tyrosine kinase receptor blocker 4-[(4′-
Chloro-2′-fluoro)phenylamino]-6,7-chimothoxyquina-
zoline (Calbiochem, Darmstadt, Germany). The
growth of HUVECs was measured using the sulforho-
damine-B (SRB) assay as described earlier. In short,
cells were washed twice with PBS, incubated with
10% trichloric acetic acid (1 h, 4°C), and washed in
distilled water. Cells were stained with 0.4% SRB
(Sigma-Aldrich BV, Zwijndrecht, The Netherlands) for
15 to 30 min, washed with 1% acetic acid, and were
allowed to dry. Protein-bound SRB was dissolved in
Tris (10 mmol/L, pH 9.4). The absorbance was read at
540 nm. Growth was calculated using the formula:
percentage growth = (absorbance test well / absorb-
ance control well) × 100%. 
Statistical Analysis
All data in the figures are given as mean ± SEM.
Statistical analysis was performed by using two-tailed,
independent sample “t”-test. Significance was accepted
at p ≤ 0.05.
RESULTS
Effect of ET-1 on Human ASM Cell Proliferation
In order to investigate the role of ET-1 on ASM cell
proliferation and remodeling, isolated human ASM cells
were stimulated in vitro with increasing concentrations
of ET-1 (1, 10, and 100 nM). Graphic representations of
dose-dependent increase in [3H]-thymidine incorpora-
tion are shown in Fig, 2A. ET-1 significantly increased
cell numbers at all concentrations after 48 h of incuba-
tion. There was no significant difference in the increase
in cell proliferation in relation to increase in dose of ET-
1. Figure 2B is a graphic representation of time-depen-
dent [3H]-thymidine incorporation at a concentration of
Vasoactive Peptides Induced VEGF Expression 113
Cell Biochemistry and Biophysics Volume 47, 2007
Fig. 2. Graphic representation of human airway smooth muscle (ASM) cell proliferation in relation to endothelin (ET)-1.
A: Dose-dependent increases in [3H]-thymidine uptake in ASM cells after 48 h stimulation with increasing concentrations
(0, 1, 10, 100 nM) of ET-1. B: Time course of [3H]-thymidine uptake in ASM cells after stimulation with 10 nM of ET-1. Data
represent mean fold increase in relation to control from three independent experiments performed in quadruplicate. Values
are shown as mean ± SEM. *p ≤ 0.05 vs the control serum-deprived cells.
10 nM of ET-1. After 48 h of stimulation, we found sig-
nificantly increased cell proliferation as measured by
thymidine incorporation as compared to the control cells
(13.6 ± 1.9 × 103 CPM vs 8.9 ± 0.8 × 103 CPM). Thereafter,
cell proliferation induced by ET-1 was significantly
higher than the control even up to 96 h of treatment.
VEGF mRNA Expression in Relation 
to ANG II and ET-1
Human ASM cells were treated for 30 min, 1, 2, 4, 8,
16, and 24 h either with ANG II (100 nM) or ET-1 (10 nM)
in order to examine the VEGF mRNA expression. Using
Northern blot hybridization, we detected two mRNA
species of 3.9 and 1.7 kb encoding VEGF in human ASM
cells treated with ANG II (Fig. 3A) and ET-1 (Fig. 3B). In
order to compare the expression pattern and to verify
the integrity of total RNA samples, GAPDH, a house-
keeping gene, was used to re-hybridize the membranes.
A strong, dark band at 1.4 kb, hybridizing to a cDNA
insert encoding GAPDH in each RNA preparation, is
visible (Fig. 3, lower panels). As shown in the blot and in
the graphs expressing the relative mRNA levels, stimu-
lation with ANG II induced the expression of VEGF
mRNA reaching maximal levels at 2 h, whereas ET-1
induced VEGF mRNA expression peaked at 4 h and
remained elevated as compared to serum-free controls.
Serum also induced mRNA expression of VEGF in
human ASM cells in vitro (data not shown).
ANG II- and ET-1-Induced Release of VEGF 
From Human Airway Smooth Muscle Cells
The effects of ANG II and ET-1 on VEGF release in
human ASM cells are shown in Fig. 4. Conditioned
media obtained from ANG II (100 nM)- and ET-1
(10 nM)-treated human ASM cells were assessed for
the VEGF release using the ELISA method. In our
study, we observed a time-dependent release of VEGF
from human ASM cells treated with ANG II and ET-1.
We found a significant increase in VEGF concentration
in conditioned medium from ANG II-treated ASM
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Fig. 3. Angiotensin (ANG) II- and endothelin (ET)-1-induced expression of vascular endothelial growth factor (VEGF) in
human airway smooth muscle (ASM) cells. A representative Northern blot showing a major 3.9- and a minor 1.7-kb mRNA
band of VEGF. Total RNA from control and treated human ASM cells was hybridised with a cDNA insert encoding human
VEGF. Growth arrested cells were incubated with ANG II or ET-1 in serum-free growth medium for the times indicated on
the top. Filters were rehybridized with GAPDH cDNA probe for reference purposes.
cells at 4 h of incubation (391 ± 28 pg/mL) as com-
pared to the control (237 ± 39 pg/mL) (Fig. 4A). In the
conditioned medium from ET-1-treated cells, we found
significant increase at 4 h (397 ± 60 pg/mL) and 16 h
(413 ± 40 pg/mL) and then the levels of secreted VEGF
remained elevated at later time points (Fig. 4B).
However, ANG II induced the secretion of VEGF pro-
tein in a transient manner where the levels declined
after 8 h of incubation. 
Effects of ASM-Conditioned Medium on DNA
Biosynthesis and Cell Number in Porcine
Pulmonary Artery Endothelial Cells
To decipher the angiogenic potential of the condi-
tioned medium obtained from vasoactive proteins
treated human ASM cells, proliferation assays were
conducted on porcine pulmonary artery endothelial
cells. Figure 5A shows significant increase in [3H]-
thymidine incorporation after 24 h treatment with con-
ditioned medium from ET-1-treated ASM cells (2.4 ± 0.5
× 103 CPM), 5 ng/mL VEGF (1.07 ± 0.3 × 103 CPM) and
5 ng/mL PlGF (1.07 ± 0.2 × 103 CPM) as compared to
serum-free control cells (0.35 ± 0.06 × 103 CPM).
However, the conditioned medium obtained from
ANG II-treated human ASM cells did not induce sig-
nificant proliferation (0.48 ± 0.6 × 103 CPM) as com-
pared to the control. Similarly, the cell count
experiments revealed enhanced cell numbers (two- to
fourfold) after treatment with the conditioned medium
from cells treated with ET-1, VEGF, and PlGF at 48 h
(Fig. 5B).
Inhibition of Conditioned Medium-Induced
Endothelial Cell Proliferation by VEGF 
Receptor Blocker
To verify the potential mitogenic activity of VEGF
secreted from ET-1-treated human ASM cells, a
HUVEC-based cell proliferation model was exploited.
Serum-deprived cultured HUVECs were pretreated
with the VEGF receptor tyrosine kinase inhibitor (VRI)
prior to treatment with the conditioned medium of ET-
1-treated human ASM cells and the data is shown in
Fig. 6. We observed a significant increase (1.45- ± 0.23-
fold) in HUVEC proliferation when cells were incu-
bated with conditioned medium as compared to
respective control cells (p < 0.05). However, pretreating
the HUVECs with VRI showed a drastic inhibition in
HUVEC proliferation as compared to cells without the
VRI pretreatment (p < 0.001) as well as in comparison to
control cells (p < 0.05).
DISCUSSION
In this study, we have shown that ET-1 induced a
time dependent DNA biosynthesis in cultured human
ASM cells. We have previously demonstrated the mito-
genic and hypertrophic potential of ANG II in human
ASM cells (26). Furthermore, both ANG II and ET-1
induced the mRNA expression and secretion of VEGF
from human ASM cells. The conditioned medium
derived from ET-1-treated ASM cells induced cell pro-
liferation in porcine pulmonary artery endothelial as
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Fig. 4. Time-dependent production of vascular endothelial growth factor protein in relation to angiotensin (ANG) II or
endothelin (ET)-1. Growth-arrested human airway smooth muscle (ASM) cells were stimulated with 100 nM ANG II or 10
nM ET-1 for various time points. Control cells (C) received serum-free medium. Data represent the mean ± SEM of tripli-
cate values from independent experiments using conditioned medium from ASM cells cultured from four patients. *p ≤ 0.05
as compared to respective controls.
well as human umbilical vein endothelial cells and
VEGF tyrosine kinase receptor inhibitor blocked the
conditioned medium induced mitogenesis in endothe-
lial cells. These results suggest that ANG II and ET-1
contribute differentially to human ASM cell growth and
upregulation of VEGF for paracrine action on endothe-
lial cells, which could potentially lead to angiogenesis
and vascular remodelling during chronic airway dis-
eases. Besides regulating the bronchial tone and con-
tributing to the hyper responsiveness (31), studies have
clearly shown the important role of ASM in the perpet-
uation of inflammation by its enhanced secretory nature
and thus contributing to the remodelling process in
chronic airway diseases. Remodeling is a complex
process (32) involving cell migration, proliferation,
angiogenesis (2), and extracellular matrix alteration
(33), ultimately leading to a modified airway vascular
structure.
In our study, we used confluent human ASM cells as
a model to study the role of vasoactive proteins in
expression and secretion of VEGF, thereby mimicking
vascular remodeling pathways in airways. Our data on
the increased expression of VEGF in human ASM cells
support the notion that this angiogenic molecule is tran-
scribed and translated in these cells for paracrine action
on neighbouring endothelial cells. This is in accordance
with previous studies where its expression is regulated
by growth factors and cytokines, including tumor
necrosis factor (TNF)-α, transforming growth factor
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Fig. 5. Effects of angiogenic factors and conditioned medium obtained from angiotensin (ANG) II or endothelin (ET)-1-
treated airway smooth muscle (ASM) cells on the biosynthesis of DNA in porcine pulmonary artery endothelial cells.
Conditioned medium (CM; 100 µL) obtained from human ASM cells treated with ANG II (100 nM) or ET-1 (10 nM)-were
added to serum-deprived endothelial cells and [3H]-Thymidine incorporation array (A) and cell number (B) were per-
formed. Values are mean ± SEM from three experimental determinations. Note that vascular endothelial growth factor (5
ng/mL), placental growth factor (5 ng/mL), and fetal calf serum (FCS) are potent mitogens for the endothelial cells (p ≤
0.05). CM from ET-1 (10 nM)-treated ASM cells is mitogenic for the cells at 24 h and 48 h. However, CM from ANG II-
treated ASM cells did not elicit the mitogenic effect (p ≤ 0.05) at 24 h.
Fig. 6. Pretreatment with vascular endothelial growth
factor (VEGF) receptor inhibitor and human umbilical
vein endothelial cell (HUVEC) proliferation in response to
condition medium. Graphic representation of fold change
in percentage HUVEC proliferation in response to
Dulbecco’s modified Eagle’s medium (Control), and con-
dition medium from human airway smooth muscle (ASM)
cells treated with endothelin (ET)-1 for 8 h. Proliferation of
HUVECs with the ET-1 conditioned medium increased
significantly compared to the control. This stimulating
effect was strongly diminished in 10 µM VEGF receptor
blocker (VRI) pretreated HUVECs. Values are represented
as mean ± SEM from experiments performed in quadru-
plicate and experiments were repeated twice. * Compared
to medium alone (p < 0.05); # in relation to ET-1-treated
human ASM-conditioned medium (p < 0.05) at 48 h. 
(TGF)-β, and interleukin-1β (18,34).  Several lines of evi-
dence suggest that VEGF levels are upregulated in
patients with asthma (35,36) and COPD (2,11).
Moreover, increased expression of VEGF in asthmatic
airways with positive correlation with increase in blood
vessel number and size suggests that VEGF signifi-
cantly contribute to angiogenesis (37) and vascular
remodeling and hence to the airway wall remodeling
processes. Moreover, the mitogenic effects of the condi-
tioned medium derived from ET-1-treated ASM cells on
the pulmonary artery endothelial cells supports the
hypothesis that the VEGF synthesized by ASM under
influence of these molecules is biologically active.
However, the conditioned medium derived from
ANG II-treated human ASM cells could not result in
endothelial cell proliferation and warrants further
investigation. This could also be attributed to the sub-
threshold levels of secreted VEGF from ANG II-treated
cells as compared to ET-1-treated ASM cells. Both
mRNA and protein data on VEGF production in ANG
II-treated cells showed transient and rapid increase
which declined within 8 h indicating for degradation as
compared to stable levels in ET-1-treated cells. Also, it
cannot be ruled out that either the released VEGF is an
inactive variant or that VEGF, a known survival factor,
is being utilized by the cells rapidly. Additionally, the
fact that only ET-1 induces significant proliferation of
ASM cells, whereas ANG II induces cellular hypertro-
phy but does not increase cell numbers, as we reported
previously (26), may suggest that predominantly prolif-
erating ASM cells secrete VEGF. Inhibition of the condi-
tioned medium-induced HUVEC proliferation with the
VEGF receptor blocker clearly demonstrates and con-
firms the importance of the angiogenic molecule, VEGF
in whole milieu.
In conclusion, our study demonstrated that potent
vasoactive proteins (ANG II and ET-1), via increased
production of VEGF in proliferating human ASM cells,
could indirectly contribute to vascular remodelling and
angiogenic processes during bronchial pathophysiol-
ogy. Our previous results (2,18), and the current data
clearly demonstrate that ASM cells are an important
source of angiogenic mediators in these airways. The
mechanism underlying the signaling events leading to
the expression of VEGF mRNA in response to vasoac-
tive proteins are not entirely clear. It is now well estab-
lished that the angiogenic factors, such as VEGF,
produced by ASM cells in the vicinity of the endothelial
cells appear to be a key paracrine event in the airways
that contributes to the pulmonary vascular remodeling.
Undoubtedly, more research focus has been recently
directed towards the molecular events underlying the
airway vascular remodelling. Though the precise nature
of these events is far from clear, our study sheds a pos-
sible mechanism of vascular remodeling that could take
place in chronic airway diseases.
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